Linked Life Data

8755842

Source:http://linkedlifedata.com/resource/pubmed/id/8755842

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
1996-10-9
pubmed:abstractText
The results are presented of a clinical trial with the use of hrec TNF alpha administrated intraperitoneally in advanced cancer patients suffering from malignant ascites. Fourteen patients in a terminal phase of a neoplastic disease were treated with intraperitoneal infusions of hr TNF alpha in progressively increasing doses. The procedure was repeated maximum 8 times, with one-week intervals between each dose. Response to the therapy (complete or partial remission) was observed in 8 patients. No evidence was shown of increased survival time in the cancer patients receiving TNF alpha. However, the treatment significantly increased their quality of life, especially in its psychological and somatic aspects.
pubmed:language
pol
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0032-3772
pubmed:author
pubmed:issnType
Print
pubmed:volume
95
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
357-61
pubmed:dateRevised
2010-4-1
pubmed:meshHeading
pubmed:year
1996
pubmed:articleTitle
[Intraperitoneal use of human tumor necrosis factor (hrTNFalfa) in patients with ascites during advanced neoplastic disease].
pubmed:affiliation
Katedra i Klinika Chorób Wewnetrznych Slaskiej Akademii Medycznej.
pubmed:publicationType
Journal Article, Clinical Trial, English Abstract